secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verve Therapeutics, Inc. (—)
CIK:        0001840574
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0001193125-24-151009
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Verve Therapeutics appoints Troy Lister as CSO; Andrew Bellinger to resign effective June 21, 2024
--------------------------------------------------------------------------------

- Troy Lister, Ph.D., appointed Chief Scientific Officer effective June 21, 2024, succeeding Andrew Bellinger.
- Andrew Bellinger resigns as CSO on June 21, 2024; will provide advisory services under an Advisor Agreement.
- Bellinger receives 12 months base salary continuation, a $153,765 bonus (67% of target), and limited equity vesting.
- Advisor Agreement pays Bellinger $200/hour; cannot be terminated for convenience before two-year anniversary.
- Bellinger subject to non-compete for one year after advisor termination; non-disclosure obligations continue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840574/000119312524151009/0001193125-24-151009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840574/000119312524151009/d797150d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-151009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer